Eurofarma Laboratorios

Large Brazilian generics/specialty pharma (100% Brazilian-owned)

Privately held: no public share price · Brazil

Assets

(3 total)
3Total Assets
1Approved
2Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Cenobamate(Xcopri)
Approved
Sodium channels + GABA-A receptorsSmall molecule
Epilepsy
Focal Onset Seizures
Evogliptin(Suganon)
Phase 3
DPP-4Small molecule
Type 2 Diabetes
Phase 3
5-HT1B/1D receptor · Nonsteroidal Anti-inflammatory DrugSmall molecule
Migraine

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
January 2027 (2)
Cenobamate · XcopriPhase 2Epilepsies, Partial
Est. primary completion 2027-01-31 · NCT06590896 · CT.gov ↗
What to watch
Cenobamate · XcopriPhase 3Epilepsy, Generalized
Est. primary completion 2027-01-31 · NCT06579573 · CT.gov ↗
What to watch
2028 (1)
March 2028 (1)
Cenobamate · XcopriPhase 3Partial Epilepsy
Est. primary completion 2028-03-30 · NCT07594158 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

31 January 2027FDA action dateCenobamatePDUFA date set for cenobamate oral suspension
US, FDA · Source ↗

Recent

4 November 2026Filing submittedCenobamateSK Biopharmaceuticals submits sNDA for cenobamate in PGTC seizures and pediatric focal-onset seizures
US, FDA · SK Biopharmaceuticals · Source ↗
15 June 2026Filing acceptedCenobamateFDA accepts NDA for cenobamate oral suspension
US, FDA · Source ↗

Financial reports

No financial reports recorded.